Lisofylline (6493-06-7, racemic) displays anti-inflammatory activity. Regulates immune cell function and autoimmune response by inhibition of IL-12 signalling and cytokine production1. Protects pancreatic beta cells and prevents type I diabetes in non-obese diabetic mice2. Lisofylline reduces LPS-induced TNF alpha levels in CD-1 mice3. Cell permeable.
1) Yang et al. (2005), Lisofylline: a potential lead for the treatment of diabetes; Biochem. Phamracol., 69 1
2) Yang et al. (2002), The anti-infkammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice; Diabetologia, 45 1307
3) Wyska et al. (2010), Pharmacokinetic-pharmacodynamic modeling of methylxanthine derivatives in mice challenged with high-dose lipopolysaccharide; Pharmacology, 85 264